Podcasts about impax

With input from Lewis Research Center, now NASA Glenn, the Impax line of force measurement products was born.

In this episode of SustainabilityTalks, we hear the investor's perspective. The conversation revolves around how corporate governance reforms and various market developments around Asia are driving corporate value and investment returns, as well as around some of the exciting investment opportunities currently in focus for Impax Asset Management, the world's largest dedicated impact and transition focused investor. Listen as Natalya Oram, Director, Global Sustainability Solutions, Market & Securities Services, HSBC discusses the history of Impax and how it started, as well as the direction of travel for investors as the world transitions to a low carbon economy, with Nana Li, Head of Sustainability & Stewardship, Asia-Pacific, Impax Asset Management. Hosted on Acast. See acast.com/privacy for more information.

A NASA spinoff involving piezoelectric technology developed decades ago is still in use in sports and by Olympic trainers today.

Renewable Energy Stock Picks -- and More, covers investments in renewable energy, Canadian sustainable companies, water investments, women's empowerment, plus… By Ron Robins, MBA Transcript & Links, Episode 134, July 12, 2024 Hello, Ron Robins here. So, welcome to this podcast episode 134 titled “Renewable Energy Stock Picks -- and More.” It's presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Now, remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the actual articles for more company and stock information. Also, some companies might be covered more than once and there are also 3 article links below that time didn't allow for me to cover here. ------------------------------------------------------------- These 50 Canadian corporations are betting big on green Now nearly all the articles covered in this episode relate to renewable energy investments – except this one. Though it's about Canadian companies, many of them will be of interest to ethical investors globally. Hence, I'm beginning with it and it's titled These 50 Canadian corporations are betting big on green. The editorial is by Rick Spence and appears on corporateknights.com. “Now in its 23rd year, the Best 50 helps track how Canadian businesses are meeting the low-carbon and green-transition challenge – as well as where they're getting stuck in the process… The companies that made the Best 50 are mostly corporations with more than $1 billion in annual revenues, as well as Crown corporations, large co-ops and members of the S&P/TSX Renewable Energy and Clean Technology Index. What sets them apart is their commitment to doing business differently – they're companies that derive significant revenue from greener products and services, invest in increasingly sustainable projects, and prioritize equity in their operations. Crucially, the companies' average sustainable investment (as a percentage of total investment) hit 58.9% this year, up 9% over last year's 49.7% – that's compared to just 8.4% for the average large Canadian corporation.” End quotes. Among the top public companies on the list are Brookfield Renewable Partners LP (NYSE:BEP), Wheaton Precious Metals Corp. (WPM), Cascades Inc. (CAS.TO), and BCE Inc. (BCE.TO). ------------------------------------------------------------- 1) Renewable Energy Stock Picks -- and More So, back to the renewable energy sector with this first article titled 3 Best Renewable Energy Stocks to Buy in July 2024, According to Analysts. It's by Sheryl Sheth and seen on nasdaq.com. Here are some of her comments. “1 Fluence Energy (NASDAQ:FLNC) is engaged in empowering the global clean energy transition by providing energy storage solutions. The company also offers cloud-based software solutions for renewables and energy storage. Importantly, Fluence Energy has the backing of two industry-leading companies, Siemens (DE:SIE) and AES Corp. (NYSE:AES)… On TipRanks, Fluence Energy stock has a Strong Buy consensus rating based on 12 Buys and three Hold recommendations. The average Fluence Energy price target of $30.21 implies an impressive 83.9% upside potential from current levels. Meanwhile, Fluence Energy shares have plunged 31.1% so far in 2024. 2. ReNew Energy Global (NASDAQ:RNW) India-based ReNew Energy Global is one of the largest renewable companies in the world, with a clean energy portfolio of roughly 15.6GW (gigawatts) on a gross basis as of May 31. The company provides innovative and sustainable decarbonization solutions for corporates. Plus, it engages in the production of wind, solar, and hydropower and manufactures solar PV (photovoltaic) cells… With six unanimous Buy ratings, ReNew Energy Global stock commands a Strong Buy consensus rating on TipRanks. The average ReNew Energy Global price target of $8.82 implies 45.1% upside potential from current levels. Year-to-date, ReNew Energy Global shares have lost 19.5%. 3. Clearway Energy, Inc. (NYSE:CWEN) claims to own one of the largest renewable energy portfolios in the U.S. The company has approximately 6,200 net MW (megawatts) of installed wind, solar, and battery energy storage systems. Plus, it owns another 2,500 net MW of environmentally-sound, highly efficient natural gas generation facilities. The company believes in rewarding shareholders with generous dividend payments… With six Buys and one Hold rating, Clearway Energy stock has a Strong Buy consensus rating on TipRanks. The average Clearway Energy Class C price target of $31 implies 27.6% upside potential from current levels. Clearway Energy shares have declined 8.4% so far in 2024.” End quotes. ------------------------------------------------------------- 2) Renewable Energy Stock Picks – and More Also, related to renewable energy is this article titled 3 ESG Funds to Buy As Sustainable Investing Gathers Steam. It's by Zacks Equity Research and found at au.sports.yahoo.com. Here are some comments on their picks from the Zack's analysts. “All of these funds carry a Zacks Mutual Fund Rank #2 (Buy). In addition, the minimum initial investment for these funds is within $5,000. We expect these funds to outperform their peers in the future… Unlike most of the fund-rating systems, the Zacks Mutual Fund Rank is not just focused on past performance but also on the likely future success of the fund. 1. Fidelity Select Environment and Alternative Energy Portfolio (FSLEX) The fund invests… in securities of companies mostly engaged in activities related to alternative and renewable energy, energy efficiency, pollution control, water infrastructure, waste and recycling technologies or other environmental support services. The non-diversified fund invests in U.S. and non-U.S. issuers alike… Fidelity Select Environment and Alternative Energy Portfolio has an annual expense ratio of 0.85%, which is below the category average of 1.09%. It has returned 4.9% over the past five years. 2. Parnassus Core Equity Fund - Investor Shares (PRBLX) aims for capital growth and current income through its investments… (It)… invests in large-capitalization companies in the United States that have long-term competitive advantages and relevancy, quality management teams and positive performance in the ESG criteria… Parnassus Core Equity Fund - Investor Shares has an annual expense ratio of 0.86%, which is below the category average of 0.93%. It has returned 9.1% over the past five years. 3. TIAA-CREF Core Impact Bond Fund Retail Class (TSBRX) The fund invests (most of) … its assets in bonds. TIAA-CREF Core Impact Bond Fund Retail Class gives particular consideration to environmental, social and governance criteria… TIAA-CREF Core Impact Bond Fund Retail Class has an annual expense ratio of 0.65%, which is below the category average of 0.80%. It has returned 3.2% over the past five years.” End quotes. ------------------------------------------------------------- 3) Renewable Energy Stock Picks -- and More And here is my next renewable energy article. It's titled The 3 Smartest Renewable Energy Stocks to Buy With $500 Right Now and is by Rich Duprey and found on investorplace.com. Now some brief quotes from Mr. Duprey on each of his picks. 1. NextEra Energy (NYSE:NEE) is the first renewable energy stock that investors should consider buying. It is the world's largest generator of renewable energy from the wind and sun and a top-tier stock in battery storage. At the end of 2023, NextEra had approximately 72 gigawatts (GW) of total capacity in its portfolio. Of that amount, half or 36 GW came from renewables, some 70% more than its nearest competitor with wind power represented as two-thirds of the total renewable capacity… NextEra Energy will be one of the top renewable energy stocks to buy that leads the way. 2. Brookfield Renewable Partners (NYSE:BEP) is the leading provider of hydropower in the country. It operates as one of the world's largest publicly traded platforms for renewable power and decarbonization solutions. Yet where 85% of Brookfield's portfolio was once hydropower generation, today it stands at about 50% as the company grew through mergers and acquisitions… Although it primarily has projects in North America and Latin America, more recently as the Neoen acquisition shows, it is expanding more towards Europe and Asia. Brookfield Renewable Partners is a renewable energy stock to buy because of its hydro sector dominance that cannot be easily, or readily, replicated. 3. First Solar (NASDAQ:FSLR) is the world's leading manufacturer of thin-film solar panel technology and a pure-play in the solar panel space. It focuses on the U.S. and Indian markets where the greatest booking potential lays, particularly in the domestic utility-scale market… First Solar has built a solid financial foundation and a strong balance sheet to weather future storms. Its thin-film cadmium telluride technology is distinctive in the industry that benefits from its simple manufacturing process. First Solar should also benefit from the Biden administration's protectionist trade policies. It recently imposed high-import barriers on cheaper Chinese panels.” End quotes. ------------------------------------------------------------- 4) Renewable Energy Stock Picks -- and More This last article takes us away from renewable energy. It's titled 6 impact investing firms and funds that are top picks from U.S. News. The article's authors are staff at equities.com. Now some brief quotes from the article. “Impact investing firms 1. Eaton Vance Corp. (EV) When this investment management firm bought Calvert Investment Management in 2016, it acquired a company that's been involved in responsible investing for years. It launched an ESG bond portfolio in 1987 and a non-U.S. ESG portfolio in 1992. In 1995, it debuted Calvert Impact Capital. Now, Calvert Impact offers notes targeting community investment, carbon reduction and a more inclusive banking system. It also offers several small business recovery funds. 2. Impax Asset Management Group PLC. (IPXAF) This is another firm that grew its impact investing offerings through an acquisition. In 2017, it announced that it would buy Pax World Management. Impax has worked with the World Bank to structure an impact bond to finance 300,000 water purifiers for schools and other institutions in Vietnam… 3. Trillium Asset Management. This ESG-focused fund provider offers impact investing strategies targeting sustainable agriculture, low-income housing, job creation and retention, Native American community development, financial services that help people avoid predatory payday lenders, environmental sustainability, development of domestic and international communities and child care. It typically directs investments to nonprofit loan funds or development banks and credit unions targeting historically underserved sections of society. Impact investing funds 1. First Trust Nasdaq Clean Edge Green Energy Index Fund (QCLN) This alternative energy fund tracks an index of securities issued by companies involved in advanced materials, energy intelligence, renewable electricity generation and renewable fuels, and energy storage and conversion. The $702 million fund has an expense ratio of 0.59%, or $59 per year for every $10,000 invested. It also paid a 30-day SEC yield of 1.2% as of the end of May. (It)… is up more than 60% over the past five years, though the last few years have been rough going for the fund. 2. Invesco Water Resources ETF (PHO) This ETF tracks an index of companies involved in the conservation and purification of water for homes, businesses and industries. Most of its holdings focused on resource security and basic needs, with a smaller percentage allocated to climate action. The $2.1 billion fund has an expense ratio of 0.6% and is up more than 80% over the past five years. 3. YWCA Women's Empowerment ETF (WOMN) This fund hits on a theme that is big in the impact investing community: women's empowerment. (It)… tracks an index of companies that ‘have strong policies and practices in support of women's empowerment and gender equality,' the fund's website says. Impact Shares donates all the net advisory profits from (the fund) to the YWCA. The $56 million ETF has an expense ratio of 0.75% and is up more than 74% over the past five years, beating its category average.” End quotes. ------------------------------------------------------------- Honorable Mentions that time didn't allow me to cover here 1. Title: 7 Investments That Make You Feel Good While You Make Money on aol.com. By Laura Bogart. 2. Title: Top 10: Climate Tech Unicorns on sustainabilitymag.com. By Marcus Law. Honorable Mentions From the UK 1. Title: Top 10 most-purchased ETFs in June 2024 on ii.co.uk. By Sam Benstead. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast titled: “Renewable Energy Stock Picks -- and More.” Now please click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps to improve these podcasts' ratings and bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these very troubled times! Contact me if you have any questions. Thank you for listening. I'll talk to you next on July 26th. Bye for now.   © 2024 Ron Robins, Investing for the Soul

In this episode, host Kimberley Dondo chats with Fotis Chatzimichalakis of Impax Asset Management about shifts in sustainable investing, Impax's strategy updates, and future predictions. Gain insights on advisor support and emerging market trends. Listen now:  

In this episode of the Investors Champion podcast, hosts Chris and Lee discuss the challenges faced by companies like National Grid and UK water companies in balancing dividends with capital expenditure. They delve into recent market moves including the ECB's rate cuts and UK construction's growth, and evaluate the potential undervaluation of Tesla amidst its diverse technology portfolios. The episode highlights various UK stocks, such as Ramsden's, WH Smith, and Fever Tree, and investigates the financial health and future prospects of these companies. Fund managers like Polar Capital and Premier Miton are also examined for their potential growth and dividend yields. The podcast concludes with a look at bonkers bargains like Gemfields, promising opportunities for shrewd investors. Timestamps: 01:17 Weekly News and Stock Updates 01:45 ECB Rate Cuts and UK Construction Boom 04:01 National Grid's Financial Struggles 10:47 NVIDIA's Market Milestone 13:51 Tesla's Valuation Debate 16:11 Fund Managers Premier Miton, Impax, Lion Trust and Market Trends 18:03 Dividend Payers and Market Outlook 19:16 Pawn brokers Ramsdens and HT&T 22:43 WHSmith: High Street vs. Travel Retail 28:24 Investment Insights: Trustpilot and Tech Giants 30:56 Quick Company Reviews: Fever Tree, InSpec's Group, and Gemfields Hope you enjoy this episode and have a wonderful day. If you like this episode, please let us know by subscribing for future company reviews and insightful conversations about the markets, portfolio management and stock analysis. Links & Resources: Visit Investor's Champion website here: https://www.investorschampion.com/ Follow Investor's Champion on X here: https://twitter.com/investchampion  Disclaimer: This presentation is for educational purposes only. All opinions and information are for demonstrational purposes and do not constitute investment advice. Trading and investing carries a high level of risk and are not right for everyone. If you need financial advice, consult with a regulated financial adviser in your country before making any decisions.  

Founded in 1998, Impax Asset Management is a pioneer in investing in the transition to a more sustainable economy. On this episode of the ESG Currents podcast, Ian Simm, Impax's Founder and CEO, joins Eric Kane, Bloomberg Intelligence's director of ESG research, to discuss the evolution of the ESG space, single vs. double materiality, net zero vs. net-zero aligned, the complexity of biodiversity, why “green is not black and white” and much more. This episode was recorded on Feb. 12.See omnystudio.com/listener for privacy information.

In this conversation, Alex Sheridan from Impax discusses with Dustin the importance of sharing content online and the power of video for B2B companies. Alex emphasizes the need for companies to be more involved in the content creation process and highlights the benefits of creating buyer-ready content. He also shares common mistakes B2B companies make with in-feed social content and the importance of understanding the buyer's mindset on different social media platforms. Finally, Alex introduces the concept of video as a 24/7 sales rep and offers guidance on getting started with video content. If you have any questions or thoughts, you can reach out to Alex through LinkedIn. Also, check out Impaxs' website to learn more about their work.

Bloomberg Intelligence Senior Technology Analyst Anurag Rana joins to recap IBM earnings. Bloomberg Intelligence Senior Aerospace, Defense & Airlines Analyst George Ferguson joins to discuss earnings from airlines this week. Charlie Donovan, Senior Economic Advisor at Impax, joins to talk about issues affecting sustainable energy investing. And Dan Ives, Managing Director & Senior Equity Analyst at Wedbush Securities, joins to recap Tesla earnings.  Hosts: Alix Steel and Paul SweeneySee omnystudio.com/listener for privacy information.

In this episode of ESG in 10, Charlotte is joined by Moana Nottage, Alphinity Investment Management, and Nana Li, Impax Asset Management, to share insights from the PRI in person conference held in Tokyo in October, and discuss the emerging themes that are the focus of investors globally.  

The world is experiencing an acute inflation shock, but one key question we must ask, is how this impacts the transition to a sustainable economy?  If we don't get the transition right, could it worsen future inflation hurdles? With a career spanning over 25 years in sustainability, Kirsteen Morrison, Portfolio Manager at Impax Asset Management, joins the podcast to share her insights on how the current inflationary environment will impact the transition to a sustainable economy and what the failure to act on climate change may mean for the inflationary environment in the future.

The U.S. president of the firm, who's retiring after this year, tells Investing IN Change where sustainable investing is headed and what's going on with the political divide on a seemingly apolitical subject. Plus, Paul and Emile get into the details of the first lawsuit over ESG use in a 401(k) plan.Related Article: Impax North America president Keefe to retireGuest Bio:Joe Keefe is president of Impax Asset Management. Based in the Portsmouth office, he is responsible for distribution of Impax's full capabilities across North America. 

The Joint Venture: inspiratia insightsThe team looks over the past week of news in the energy industry and give their views on some big market trends - joined by special guest Scott Lawrence Scott is a founding partner of Glennmont Partners, leads all of the firm's solar initiatives and is actively involved in new financing initiatives. Scott has worked in renewable energy power generation for more than a decade, leading many of the investments across Glennmont's fund platform. Prior to founding Glennmont Partners, Scott was the co-founder and director of Windsor Alternative Investments – a company formed to finance and develop solar power plants in Europe. Before focusing on renewable energy, Scott was involved in private equity acquisitions and debt capital finance for commercial real estate transactions in Europe and the United States. Also on this episode, we cover some of the standout announcements of the last week. Rob brings us up to date on the latest moves from Gresham House and Foresight, how Impax is considering a move towards hydrogen, and the European Investment Bank is backing improvements to the Portuguese grid. We also take a first look at the UK government's Energy Security day as Dila brings us the latest details and puts the government moves in some context.   Hosted by:Oliver Carr - Senior Hydrogen AnalystRobert Leeming - Head of NewsDila Cebeci - Senior Infrastructure AnalystReach out to us at: podcasts@inspiratia.comFind all of our latest news and analysis by subscribing to inspiratiaListen to all our episodes on Apple Podcasts, Spotify, and other providers.

Fotis Chatzimichalakis, Portfolio Manager at Impax Asset Management joins Kimberley Dondo in the latest episode of In Conversation With. They discuss an overview of the UK's largest environmental trust and the challenges facing green trusts.  

The topics, stocks and shares mentioned/discussed include: Quality compounders winning checklist Argentex / AGTX Goodwin / GDWN Crestchic / LOAD K3C Capital Group / K3C Impax AM / IPX Foresight Group / FRG Games Workshop / GAW Record / REC Forex provider / FX / Currency volatility Harmony Energy Income Trust / HEIT Gore Street Energy Storage Fund / GSF Remy Cointreau / RCO Renewables Bioventix / BVXP AEW UK REIT / AEWU ME Group / MEGP FTSE 100 FTSE AIM All-share Small Caps GILTS Dividends / Yields REITS FDM Group / FDM Santa Rally Amber Flags Value indicators Investing Trading Charity & more The Twin Petes Challenge 2022 / Charity fundraise for the BACK UP Charity. Please make a donation, every pound will help. Thank you. Menphys Christmas List Charity Appeal : Please make a donation, every pound will help. CLICK HERE Thank you. The Twin Petes Investing podcasts will be linked to and written about on the Conkers3 website and also on the WheelieDealer website . Thank you for reading this article and listening to this podcast, we hope you enjoyed it. Please share this article with others that you know will find it of interest. PLEASE SUBSCRIBE TO THE TWIN PETES INVESTING PLATFORM THAT YOU ARE LISTENING TO THIS PODCAST ON. THANK YOU.

Founded in 1998, Impax Asset Management (Impax) is a London based specialist asset manager, investing in the opportunities arising from the transition to a more sustainable global economy. Impax has pioneered sustainable investment and today is one of the largest investment managers dedicated to this area. Impax seeks to invest in higher quality companies with strong business models and governance that demonstrate sound management of risk whilst being able to adapt intelligently to changing conditions (See Video link: The Next Economy – The Sustainable Economy).    In this interview I discuss Impax's Sustainable Leaders Fund with Sinéad Rafferty, Senior Investment Specialist at Fidante Partners. In addition to writing market insights and thought leadership, Sinéad presents to advisers and clients across various investment strategies and asset classes. She has 18 years' experience in the investment management industry across equities, fixed income, alternative assets and derivatives and also worked as a futures and options trader for a number of years.  She has a Bachelor of Commerce, Masters in Finance and is a CFA Charterholder. I hope you enjoy this conversation with Sinéad Rafferty of Impax. You can check out Impax at https://impaxam.com. For more information about James Baird and JustInvest Financial Planning see: justinvest and ethicalinvestment.  We wish to acknowledge the traditional custodians of the land we recorded on, the Wardandi Noongar people. We pay our respects to them and their culture; and to elders past, present and emerging. 

Sky's business presenter is joined by the Chief Executive of Travelex to discuss their results after a tricky few years. Ian King finds out more about online wholesale marketplace Faire and discusses overseas investment in science and innovation with government minister George Freeman. He's also joined by Swedish tech entrepreneur, Konrad Bergström who's behind the electric boat company, X Shore.

Joe Keefe, president of Impax Asset Management and the Pax World Funds, says that there are enough positives for the economy right now that he would bet against a hard landing and a protracted recession, although he acknowledges that wildcards like war in Ukraine, trade tensions with China, political issues and more to make him "barely optimistic" that a "soft-ish landing" lies ahead. Also on the show, David Trainer of New Constructs highlights Rivian Automotive as another "zombie stock," pushed to death's door by rising interest rates and higher borrowing costs that he expects can sink the company from here, and Eric Sterner, chief investment officer at Apollon Wealth Management, talks ETFs and stocks in the Market Call.

It's not been an easy year for environmentally focused funds, as the market rotation into value-focused equities has delivered a body blow to the share prices of the many innovative growth companies seeking solutions to global environmental problems. Our guest on this week's pod is Jon Forster, co-manager of the Impax Environmental Markets investment trust. IEM is the largest in the closed-ended sector at more than £1.3 billion AUM; it soft-closed to new investors in 2020. Forster talks to Faith Glasgow about how the environmental market universe has changed over the past 20 years since IEM launched, the macro challenges of the past few months and how the managers have used that market volatility, and the key opportunities emerging within this rapidly evolving investment arena. See acast.com/privacy for privacy and opt-out information.

Jon Forster discusses the lessons of two decades running the pioneering £1.4bn Impax Environmental Markets investment trust and new opportunities created by an accelerated transition to green energy as a result of the war in Ukraine.  

“The really important thing I think about this rule (from the SEC),” Dr Gorte explained, “is that if companies are going to be on the record as having a certain level of emissions, especially as climate change gets worse, there's going to be increasing scrutiny and pressure on them to reduce those emissions." Dr. Julie Gorte on Electric Ladies Podcast The Securities and Exchange Commission, the SEC, recently announced long-awaited proposed rules for how publicly-traded companies will need to report the risk to their businesses from climate change in their audited financial statements. This is a really big deal. What does it mean?   “The SEC's statutory authority is to make sure that investors have the information they need to make informed, reasonable investment decisions,” Dr. Julie Gorte, Senior Vice President of Sustainable Investing at IMPAX Asset Management and a veteran ESG investment advisor, told me in an extensive interview about these new rules on Electric Ladies Podcast. ESG is environment, social and governance-focused investing, which is also a business strategy now. Listen to Julie Gorte explain what these proposed rules mean exactly and more in this fascinating conversation with Electric Ladies podcast host Joan Michelson. You'll hear: What ESG-focused investing is and how it can have an impact to address climate change. Why the SEC is taking action now and why it's proposing new disclosure rules. What companies will have to disclose going forward in their financial statements How we will be able to rely on them…and much more Plus, great career advice.... “The best career advice I ever got was when I was leaving academia when I had just about gotten my PhD and I had these two job offers… One of my professors said, Julie, you don't have to decide what you're gonna do for the rest of your life. You need to decide what you're gonna do next. And that just, it sounds so obvious, but it just absolutely liberated me. And so I took the path less trodden, to quote Robert Frost, and my entire career has turned out really well, but not because of a plan. The only the thing that I've always followed is what I wanted to do.” Dr. Julie Gorte on Electric Ladies Podcast Read Joan's Forbes article about the interview and the SEC climate rules here, and others on ESG & Ukraine here, on ESG actions here and on the new ESG economy here. You'll also want to listen to (some of these are under the name Green Connections Radio): Kathleen McQuiggan, Veteran ESG investment manager focused on supporting women's financial success. Gabrielle Rubenstein, Managing Partner and Founder, Manna Tree Partners, investors in food companies making our food supply more transparent and healthier. Kristen Sullivan, Deloitte Sustainability & Supply Chain practice, on companies “doing” ESG. Gillian Tett, Financial Times, from COP26, about what the new financial alliance means for a net zero economy.   Michele Wucker, thought leaders and author of “You Are What You Risk: The New Art & Science to Navigating an Uncertain World.” Sandrine Dixson, Co-president of the Club of Rome (global leaders), on the new ESG economy.   Subscribe to our newsletter to receive our podcasts, blog, events and special coaching offers.. Thanks for subscribing on Apple Podcasts or iHeartRadio and leaving us a review! Follow us on Twitter @joanmichelson   and @electricgalspod

Opinions expressed are those of the speakers as of the date of publication, are subject to change without notice and do not necessarily reflect Mercer's opinions.Bitcoin and Gold are often compared to one another with Bitcoin having even been referred to as “digital gold”. In this episode, Nick White, Matt Scott and our special guest Urs Bolt, discuss the similarities, differences, and obstacles Bitcoin faces to make it mainstream amongst institutional investors.Guest speaker: Urs BoltUrs has 30 plus years' experience in the financial services industry, mainly in wealth management, investment banking and banking technology business. His core expertise is to develop and roll out new digital business platforms. Urs' current focus is helping FinTech and WealthTech companies and financial service providers review/refocus business strategies.Urs is co-initiator of the Swiss Open Wealth Association with the goal to accelerate the development of new ecosystems in wealth management and private banking. Beside that he actively contributes to the progress of the Swiss and global ecosystem in crypto finance as an opinion leader and a passionate lecturer in ecosystems in crypto finance in post-graduate courses. This content is for institutional investors and information purposes only. It does not contain investment, financial, legal, tax or any other advice and should not be relied upon for this purpose. The materials are not tailored to your particular personal and/or financial position. If you require advice based on your specific circumstances, you should contact a professional adviser. Impax is a Manager rated by Mercer.  Impax has not been paid by or received any compensation from Mercer for participating in this podcast. Please see Mercer's conflict of interest disclosure link in the Important Notices for additional information.   Read our full important notices - click here

Opinions expressed are those of the speakers as of the date of publication, are subject to change without notice and do not necessarily reflect Mercer's opinions. Carbon emissions have understandably been a key focus for attention to avoid or diminish the climate crisis. However, a wider lens is needed to sustainably service the food, water, housing, labor and transport needs of almost eight billion people. Biodiversity, adequate freshwater supplies and topsoil management are needed for food security; minerals for electric vehicles; and energy from sources such as nuclear and gas, given the intermittency of renewables. Put simply, a resource transition is needed, not simply an energy transition!  To discuss, Nick White Global Strategic Research Director, Mercer is joined by our guest speakers from Impax Asset management. Chris Dodwell, Head of Policy and Advocacy, with over 25 years' public and private sector experience in climate change, sustainable energy and environmental policy and regulation and David Li , Senior Portfolio Manager who co-manages both the Asian Environmental Markets Strategy and Asian Opportunities Strategy.  This content is for institutional investors and information purposes only. It does not contain investment, financial, legal, tax or any other advice and should not be relied upon for this purpose. The materials are not tailored to your particular personal and/or financial position. If you require advice based on your specific circumstances, you should contact a professional adviser. Impax is a Manager rated by Mercer.  Impax has not been paid by or received any compensation from Mercer for participating in this podcast. Please see Mercer's conflict of interest disclosure link in the Important Notices for additional information.    Read our full important notices - click here 

We are continuing our series on sustainable investing. We have so far talked about proxy voting and impact bonds. And today we're going to talk a little bit about investing for the future. What does that mean? Well, that means we're welcoming one of my dear partners, Emily Lee from Impax Asset Managers. She is the Vice President of Business Development and a key partner that I utilize in my investment management when it comes to sustainability for my clients. Impax has been around for 50 years, so they're not new to this game, and neither is Emily. We're going to talk focusing on where we are right now and the growing popularity of sustainable investing, what impact women and future generations have on sustainable investing, and then what you, as the end investor, can really make an impact on. So I hope that you'll tune into today's episode and share this free educational resource, as well. Sharing doesn't cost you anything but it us to spread even more education and awareness.  Find out more about Forethought Planning: www.forethoughtplanning.comFollow Forethought Planning on social media:FacebookLinkedInYouTube channelScore our free Wealth Assessment tool on our website.Securities offered through LPL Financial, a member of FINRA/SIPC. Advisory services offered through Advisors' Pride, a SEC registered investment advisor. LPL Financial, Advisors' Pride, Forethought Planning and the guests of Thrive For[e]ward podcast are separate and unaffiliated parties. Lisa Harris and Lisa Harris & Co are not affiliated with Forethought Planning, Advisor's Pride, or LPL Financial. The views expressed here are those of the participants, and not those of Forethought Planning, Advisor's Pride, or LPL financial. The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. LPL Financial and Forethought Planning do not offer legal services.   Securities offered through LPL Financial, a member of FINRA/SIPC. Advisory services offered through Advisors' Pride, a SEC registered investment advisor. LPL Financial, Advisors' Pride, Forethought Planning and the guests of Thrive For[e]ward podcast are separate and unaffiliated parties. Lisa Harris and Lisa Harris & Co are not affiliated with Forethought Planning, Advisor's Pride, or LPL Financial. The views expressed here are those of the participants, and not those of Forethought Planning, Advisor's Pride, or LPL financial. The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. LPL Financial and Forethought Planning do not offer legal services. 

Join Chris and Alex Sheridan as they discuss the ins and outs of LinkedIn and digital branding. Alex shares his journey about becoming an entrepreneur of Impax and how he has helped hundreds of people with their own businesses.

Join us for this week's Network Update! Network General Manager, Roger Lonnquist, tells us the important prayer requests for this week - including praying for weather and safe delivery of our new replacement Helena transmitter, as well as the safe delivery of the ImpaX players and Go Tell radio units as they are being shipped to Tanzania. Listen, be encouraged, pray, and share!

We have a glorious update to share for last week's Thanksgiving Outreach! God did AMAZING things through you, His people, reaching out to others in need! We also have some important prayer requests regarding the Impax players delivery to Tanzania. Listen, be encouraged, pray, and share!

In this podcast, CII Senior Research Analyst Lucy Nussbaum discusses CII's new bibliography and the importance of empirical research on ESG factors and firm value with Julie Gorte, the Senior Vice President of Sustainable Investing at Impax Asset Management.

Welcome to the Her Two Cents Podcast where your hosts Laura Webb and Faith Doyle come together as two female financial advisors with over 40 years of collective experience to provide a multigenerational perspective on all things money. Our goal is that through these conversations, we can normalize the way women talk about and view money. What if we told you that you could have an impact on the world by the way you choose to invest? Well, in this episode we explore how to invest with your values. Jenifer Cannon, VP, PAX Elevate Impax Asset Management helps us understand the terms sustainable, ESG, and Impact investing. We also dive into the evolution of these investments and dispel the myths surrounding them. Take a listen to find out how socially responsibility can be achieved through your investments. To find out more about Jenifer Cannon and Impax Asset Management visit their website at www.impaxam.com Pax World Funds are distributed by ALPS Distributors, Inc. Jenifer Cannon is a registered representative of ALPS Distributors. Inc. Investments in the Funds involve risk, including loss of principal. You should consider a Fund’s investment objectives, risks, and charges and expenses carefully before investing. For this and other information, visit impaxam.com for a fund prospectus and read it carefully before investing. See omnystudio.com/listener for privacy information.

The co-manager of Impax Environmental Markets investment trust talks to interactive investor’s head of markets Richard Hunter about the trust’s objectives and top holdings, as well the reasons for his optimistic outlook amid an accelerated transition to renewable energy. This material is intended for educational purposes only and is not investment research or a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy. The value of your investments can rise as well as fall, and you could get back less than you invested. The investments referred to may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser. Past Performance is not a guide to future performance. Interactive Investor Services Limited is authorised and regulated by the Financial Conduct Authority.

Impax Laboratories, Inc. v. FTC

Kyle Caldwell, deputy editor of Money Observer, and editor Faith Glasgow discuss the latest news for fund investors, including the dividend drought, and star fund manager Terry Smith’s verdict on the recent market sell-off. The episode includes an interview with Bruce Jenkyn-Jones, co-manager of the Impax Environmental Markets investment trust, which is both a constituent of interactive investor’s ACE 30 list of rated ethical funds and a Money Observer Rated Fund. Finally, interactive investor’s Dzmitry Lipski outlines how funds in interactive investor’s Super 60 list fared in the first quarter. This material is intended for educational purposes only and is not investment research or a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy. The value of your investments can rise as well as fall, and you could get back less than you invested. The investments referred to may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser. Past Performance is not a guide to future performance. Interactive Investor Services Limited is authorised and regulated by the Financial Conduct Authority.

Jeff Cossette talks with Julie Gorte, senior vice president for sustainable investing at Impax Asset Management and Pax World Funds, about how she engages with corporate boards over climate risk.

Tim McCorkle, with Impax Automation, LLC., is on the Small Business Celebration podcast this week and he’s going to guide us in the importance of: 1. How to grow slow and steady. 2. Be practic-able, practical - achievable… 3. Why you shouldn’t be identified by your business.

In this episode we are asking a simple but fundamental question about commercial real estate: why should companies and investors look to invest? Paul Shearer is joined by the episode sponsor - Roger Clarke (IPSX). He is also joined by Deborah Lloyd (The Association of Real Estate Funds), and Mickola Wilson (Seven Dials Fund Management). Topics covered in this episode: Roger takes us through; What is commercial real estate? How big is the market? And what do we actually mean when we talk about the types of properties that would be listed on IPSX? Who, and what type of structure, owns this commercial real estate? Where does property lie on the spectrum of risk when compared to bonds and equities? How does property in general compare to other asset classes? What is IPSX, and how does it differ to the status quo of property investment? For further information on the stats discussed in this episode, click here Roger Clarke Managing Director and Head of Capital Markets, Roger Clarke, has been a Senior Advisor to IPSX Group since January 2019. He now joins the business full time. Roger has extensive experience in corporate transactions, particularly in equity capital markets but also in M&A and restructuring, with a specific sector focus on Real Estate. Roger joins from M7 Real Estate, where he was Head of Corporate Finance, with responsibility for executing significant corporate transactions. https://www.ipsx.com/ Paul Shearer Paul Shearer has worked extensively in both Television and Radio in front of and behind the camera as an actor, writer and presenter and script editor. As a journalist he has written for both The Times and The Financial Times on residential property. He has written and presented video work on commercial property for consulting real estate agents GVA Bilfinger as well as Capita Real Estate. http://www.paulshearer.com/ Deborah Lloyd Deborah Lloyd is the current Chairman of the Association of Real Estate Funds and until 2015 was the Vice Chairman of the Management Board of INREV. She is also a non-executive board member of Kames Target Healthcare Fund, a consultant to the student accommodation fund manager, Curlew Capital and a member of the University of London’s property committee. Until 2016 Deborah, for 23 years, was a Partner at law firm Nabarro LLP, now part of CMS, where she co-founded the Funds and Indirect Real Estate team, which is ranked tier 1 in Legal 500. At Nabarro she set up and advised on funds for institutional and private equity fund managers including Aviva Investors, Standard Life, Henderson, Knight Frank, Cromwell, Kames Capital, iQ, Catalyst Capital, Rockspring, Aberdeen (SWIP), IMPAX, Curlew Capital, Eskmuir Asset Management. Deborah has a legal background in direct real estate, so understands real estate as an asset class from a development and leasing perspective. https://www.aref.org.uk/ Mickola Wilson Mickola is joint owner of Seven Dials and joined in 2008.Prior to this she was CEO of Teesland plc a listed property fund and asset management company with a cap value of the order of £200m, with over £5bn of funds under management across UK, Western and Central Europe. Prior to that she was MD of Guardian Properties, part of GRE, with responsibility for their property investment funds. https://www.7dials.com/

1. Organic solvents and MS susceptibility: Interaction with MS risk HLA genes 2. AAN 2018 Controversies in Neurology plenary: Andrea Leigh Haller and David Perez discuss primary caregivers for functional disorder patientsDr. Stacey Clardy talks with Dr. Anna Hedström about her paper on exposure to organic solvents and the associated risk of developing multiple sclerosis, followed by a discussion with Dr. Alberto Espay, Dr. Andrea Leigh Haller, and Dr. David Perez on who should be the primary caregivers for functional disorder patients. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Drs. Hedström, Leigh Haller, and Perez report no disclosures. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; and receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation, and the NIH.

1. Featured Article: Longitudinal analysis of impulse control disorders in Parkinson disease2. What's Trending: Frontiers in Neuroscience plenary interview from 2018 Annual MeetingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 17, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. Alexis Elbaz about his paper on impulse control disorders in Parkinson disease. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. Jeff Lichtman on connectomics. The interview was recorded at the 2018 AAN Annual Meeting in Los Angeles.DISCLOSURES: Drs. Crowell and Lichtman reports no disclosures. Dr. Elbaz has received research support from Agence nationale de la recherche (ANR), Agence nationale de sécurité du médicament et des produits de santé, JPND (Joint Programme - Neurodegenerative Disease Research), Institut de santé publique (IRESP), French ministry of agriculture, and Anses (government agency for food and environment safety). Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

Today in FirstWord:

Show description/summary:1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update2) Neurology Today® paper on Parkinson disease and autoimmunityIn the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.All other participants report no disclosures.

Show description/summary:1) On being sick: Musings about kindness, side effects, and slowing down2) Resident & Fellow Section Update: Annual Writing AwardIn the first segment, Dr. Alberto Espay talks with Dr. Ted Burns about his Special Editorial, “On being sick: Musings about kindness, side effects, and slowing down.” In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. John Millichap on the annual Resident & Fellow writing award. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.

Show description/summary:1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH.Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.

Show description/summary:1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports2) What's Trending: Biomarker validation and precision medicine in Parkinson disease.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation.All other participants report no disclosures.

Show description/summary:1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson diseaseOur podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.

1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.

1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy2) e-Pearl topic: Alien limb phenomenon3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics.DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.

1) Progression of brain atrophy in PSP and CBS over six months and one year2) What's Trending: Interview with Mike Amery about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Adam Boxer about his paper about on progression of brain atrophy in progressive supranuclear palsy and corticobasal syndrome. Dr. Ted Burns is interviewing Mike Amery for our “What's Trending” feature of the week about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act. In the next part of the podcast Dr. Alberto Espay interviews Dr. Rodger Elble on the topic of “how to approach” tremor disorders.DISCLOSURES: Dr. Morgan is a consultant for Impax, Lundbeck Inc., National Parkinson Foundation, Teva Pharmaceutical Industries Ltd., and Veloxis; serves on the speakers' bureau of Impax and Teva Pharmaceutical Industries Ltd.; received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic co; receives research support from National Parkinson Foundation, Parkinson's Outcome Project Grant and the NIH.Dr. Boxer serves on the scientific advisory board for Alector, Asceneuron and Delos; received funding for travel from the International Society for CNS Clinical Trials Methodology, the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium; is a consultant for Abbvie, Ionis, Janssen and Merck Serono; holds stock options in Alector and Delos; receives research support from Avid, Biogen Idec, BMS, C2N, Cortice, Forum, Genentech, Inc., Janssen, Pfizer Inc, Eli Lilly and Company, Roche, TauRx, The Tau Research Consortium, the Bluefield Project, Corticobasal Degeneration Solutions, the Alzheimer's Association and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amery is employed as Legislative Counsel for the American Academy of Neurology.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Elble receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Phytopharm, Pfizer Inc, Ortho-McNeil, Spastic Paralysis Research Foundation of Kiwanis International, Illinois-Eastern Iowa District and the NIH.

1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti2 e-Pearl topic: Juvenile Huntington Disease3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer diseaseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease.DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

1) Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review2) What's Trending: Interview with Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline3) Topic of the month: Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndromeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Lapides interviews Dr. Jan Dirk Blom about his Neurology: Clinical Practice paper on the Alice in Wonderland syndrome. Dr. Ted Burns is interviewing Dr. Clinton Wright for our “What's Trending” feature of the week about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome.DISCLOSURES: Dr. Blom receives royalties from the publication of the book Hallucinations, Research and Practice and the book A Dictionary of Hallucinations.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Wright receives royalties from UpToDate website for two chapters on vascular dementia; receives research support from American Stroke Association-Bugher Foundation Centers of Excellence project and the NIH.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as aneditorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Schmahmann serves as an editorial board member of The Cerebellum and its sister journal, Cerebellum and Ataxias; serves on the scientific advisory board for Ataxion, Inc. and Atlas Ventures; Receives royalties from the publications of the books: The Cerebellum and Cognition: International Review of Neurobiology, MRI Atlas of the Human Cerebellum, Pathways of the Brain, Cerebellar Disorders in Children: Clinics in Development Medicine, and Handbook of the Cerebellum and Cerebellar Disorders; is a consultant for Takeda Pharmaceutical Company Limited; holds stock option in Ataxion, Inc. and Atlas Ventures; receives research support from Birmingham Foundation, MINDlink Foundation, Sidney R. Baer Jr., Foundation, National Ataxia Foundation, Ataxia Telangiectasia Children's Project and the NIH.NO CME WILL BE OFFERED THIS WEEK.

1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our “What's Trending” feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India.Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.

Today in FirstWord:

1) Quality improvement in neurology: Parkinson disease update quality measurement set2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: George C. Cotzias Lecture at the AAN Meeting on antibody mediated disorders of the synapseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Drs. Janis Miyasaki and Stewart Factor about the AAN paper on new quality measures developed to improve outcomes for patients with Parkinson disease. Dr. Ted Burns is interviewing Dr. Ansgar Furst for our “What's Trending” feature of the week about his editorial on incidental findings for what's to come in amyloid plaques in traumatic brain injury. Dr. Alberto Espay interviews Dr. Josep Dalmau about his George C. Cotzias Lecture at the AAN Meeting on the topic of antibody mediated disorders of the synapse.DISCLOSURES: Dr. Miyasaki received honoraria and funding for travel from Teva Pharmaceutical Industries Ltd.; received funding for travel from Merz Pharmaceuticals, LLC; received travel honoraria from The International Parkinson Disease and Movement Disorders Society; is a consultant for Merz Pharmaceuticals, LLC; receives royalties from the publication of the book “Psychogenic Movement Disorders;” receives research support from PCORI: 2015-2018 and Parkinson Alberta.Dr. Factor served as an editorial board member of Neurotherapeutics; serves on the data safety monitoring board for Lundbeck, Inc; is a consultant for UCB; is a consultant and video reviewer for clinical trials for Avanir, Neurocrine and Auspex/Teva Pharmaceutical Industries Ltd.; receives royalties from the publications of the books “Parkinson's disease diagnosis and clinical management” and “Drug induced movement disorders;” gave expert testimony in Kmart trial (2014-2016); receives research support from Ceregene, Cynapsus, Sangamo, Teva Pharmaceutical Industries Ltd., Ipsen Pharmaceuticals, Inc., USWorldMeds, Allergen, Inc., Medtronics, Inc., Auspex, Genzyme Corporation, Michael J. Fox Foundation and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.

1) Dichlorphenamide in periodic paralysis 2) What's Trending: Editorial on the Zika Virus and what the neurologist wants to know3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Valeria Sansone about her paper on dichlorphenamide in periodic paralysis. Dr. Ted Burns is interviewing Dr. Gretchen Birbeck for our “What's Trending” feature of the week about her editorial on the Zika Virus and what the neurologist wants to know. Dr. Tesha Monteith interviews Dr. Peter Goadsby about the topic of science behind lifestyle factors: Our basic instincts and the migraine brain. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Birbeck serves as Section Editor and Curator for Without Borders mini-site Neurology®; receives research support from the NIH and Dana Foundation Neuroimaging Grant.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Goadsby serves as an editorial board member for Journal Watch Neurology; receives royalties from the publication of Mechanism and Management of Headache. (7th ed.); was a consultant for Alder Bio, Allergan, Inc., Amgen, ATI, Boehringer Ingelheim, BMS, Boston Scientific, Colucid, Coherex, DrReddy, Eli Lilly and Company, Gammacore, GlaxoSmithKline, Impax, J&J Linde Gases, Lundbeck Inc., MAP Pharmaceuticals, Medtronic, Inc., MSD, Neuralieve, Nevrocorp, Pfizer Inc, Zogenix; receives research support from Amgen and Allergan, Inc.; has worked with legal firms handling patent matters.

1) Neurology® Neuroimmunology & Neuroinflammation: Vasculitis neuropathy following exposure to minocycline 2) e-Pearl topic: Primary progressive aphasia3) Topic of the month: Neurology Today story about a wearable EEG device This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Chafic Karam about his Neurology: Neuroimmunology & Neuroinflammation paper on vasculitis neuropathy following exposure to minocycline. Dr. Ilena George is reading our e-Pearl of the week about primary progressive aphasia. Dr. Ted Burns interviews Dr. Jacqueline French about a Neurology Today story on the topic of a wearable EEG device. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Karam serves as Deputy Editor for Neurology Write Click; served on the editorial team for the Neurology® Resident and Fellow Section; received speaker honoraria from Nufactor, Inc.; received consulting honoraria from Lundbeck Inc.Dr. George serves on the editorial team for the Neurology Resident and Fellow Section.Dr. French is a consultant for Acorda Therapeutics, Anavex, Brabant Pharma, Bio-Pharm Solutions, Eisai Inc., GlaxoSmithKline, GW Pharma, Impax, Johnson and Johnson, Marinus Pharmaceuticals, Inc., Neusentis, Novartis, Pfizer Inc, Sage, Sunovion Pharmaceuticals Inc., SK Life Sciences, Supernus, Takeda, UCB Pharma, Upsher-Smith Laboratories, Inc., Ultragenyx, Vertex, Zogenix, and Zynerba, all consulting was on behalf of the Epilepsy Study Consortium, and fees are paid to the consortium and New York University receives salary support from the consortium; serves as Associate Editor for Epilepsia; serves as an Editorial board member for Lancet Neurology, Neurology Today and Epilepsy Currents; research support from Acorda Therapeutics, Alexza, LCGH, Eisai Inc., Lundbeck Inc, Pfizer Inc, SK Life Sciences, UCB Pharma, Upsher-Smith Laboratories, Vertex, NIH, and the Epilepsy Foundation.NO CME WILL BE OFFERED THIS WEEK.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Click to Subscribe to All Ben's Fitness & Get A Free Surprise Gift from Ben. Click here for the full written transcript of this podcast episode This is a jam-packed podcast episode! In the feature section  of this March 31, 2009 free audio episode,Dr. Dallas Clouatre,  a well-established author and consultant in the alternative and complimentary medicine and nutrition field, gives a compelling, thought-provoking, and incredibly informational talk on exactly how to rapidly accelerate fat loss, tone and enhance lean muscle tone using proven scientific techniques. Along the way, you'll learn some very fun and interesting facts, including: -Why fat is not a problem in your diet if you're trying to lose weight -Which nutrition compound exactly is the problem and how many pounds of it you unknowingly consume -Why something called "protein decoupling" is a key in weight loss, and how not understanding could cause failure to shed fat -How popular fat loss supplements can destroy your kidneys and leave you more likely to gain fat -A very simple explanation of why insulin is one of the prime keys to weight loss, and how even non-diabetics can have insulin resistance During this interview. Dr. Coutre doesdiscuss brand name "Impax" dietary supplements, particularly LeanFactor and ThermoFactor, mentioning the ingredients "Guggulsterones", "Forskolin" and "Advantra Z". But this is not meant to be a commercial for supplements - trust me, you're going to get alotof incredible information from this talk. Also included in this podcast episode: -Product Review: I review the cutting-edge "Yoga For Endurance Athletes" interactive DVD, which actually really impressed me, since I often don't have the time to attend, say, an hour-long yoga class. This DVD includes over 2 hours of yoga moves, but let's you "mix-n-match" your own sections, like IT bands, Shoulders, Breathing or Hamstrings. My wife and I actually were able to do a quick but highly effective 25 minute yoga workout while the kids were napping and we hit the exact sections we wanted by just selecting them on the DVD menu, without having to worry about driving to the gym, warm-up, or laying on the mat for 10 minutes afterwards (although that is an option on the DVD). There are also some pre-set routines, like "Strength", "Balance", or, my favorite, "Focus", which is supposed to get you ready for a race. Just below, here's a video with even more information and a demo. You can get the "Yoga For Endurance Athletes" DVD by clicking here. Listener Q&A: Ronnie asks: "I'm looking for a good energy drink - do spinning classes but feel quite tired through the class. I am fit but recently legs struggle a bit during class." Bob asks: "Ben, I have a couple questions. I am a relatively new triathlete (Olympic distance) and am also trying to lose about 20 pounds of body fat.  Unfortunately, I am unemployed due to the economy and have limited funds.  I have been struggling with feeling good on my workouts as well as with weight loss.  My questions are: How does stress (mental such as stress of being unemployed) affect workout and weight loss? And how would you prioritize a limited budget for weight loss/workout?  For example will I get my most bang for the buck with supplements and a store bought workout plan, or would I be better off spending all the money on a personal trainer, etc.  I know that is vague but would appreciate the guidance. Thanks as always for the great support and advice." Call-in listener Drew also has a question about too much testosterone and whether or not it could be harmful for cross country runners. Remember, you can now ask your questions via *audio* to me via the free Skype software by simply "Skyping" me at username "pacificfit". You can also call toll free to 1-877-209-9439 and leave a voicemail for Ben Greenfield. The first audioquestion I receive this week (meaning you actually have to call in via Skype or the toll-free number), will receive a FREE 3-Month Premium Subscription to TrainingPeaks, the world's top online fitness software. That's a $49 value! Special Announcements: "Holistic Fueling for Ironman Triathlon", class by Ben Greenfield, Friday, April 24, 6-7pm at Pilgrims on 1316 N. 4th Street in in Coeur D' Alene Idaho: Learn exactly how to holistically fuel the body for Ironman triathlon training and racing. Designed and taught by triathlon coach and certified sports nutritionist Ben Greenfield, this hour-long clinic will teach you how to use healthy nutrition to maximize recovery, enhance performance, delay fatigue, boost immune system and achieve your ultimate Ironman goals. Whether training or racing, you'll discover that it actually is possible to consume the thousands of necessary calories per day without sacrificing your health. You'll leave with a triathlete grocery shopping list for pre-workouts, post-workouts, race day and much, much more! Be sure to leave our podcast a rating in iTunes! Just click here to go to our iTunes page and leave feedback.

Click to Subscribe to All Ben's Fitness & Get A Free Surprise Gift from Ben. In this podcast: News From BenGreenfieldFitness.com -Shape21 Book Giveaway (http://www.shape21.com) -Ben Greenfield's Twitter page (http://twitter.com/bengreenfield). Question of the Day & Interview - Pill poppin' with Wesley and Ben Link to Supplement Article - click here The Synergy System - click here for more details Products mentioned in this show... Hammer Gel Race Caps - improves mitochondrial activity (slow twitch muscle oxidation capacity), also great for controlling effects of aging - order from http://www.hammernutrition.com , discount code 80244 Hammer Gel E-caps - electrolytes during race/longer training sessions - order from http://www.hammernutrition.com, discount code 80244 Carlson's Norwegian Salmon Oil - omega 3 fatty acids for antioxidant and joint health - order from http://www.hammernutrition.com, discount code 80244 Millennium Sports Kreaceps - creatine, load for 7 days prior to race to improve muscular force contraction; primarily for wattage on bike, force production on run, etc. - order from http://www.millenniumsports.netor by calling 1800-249-7918. Millennium Sports Citruvol - citrulline/nitric oxide, load for 7 days prior to race to improve lactic acid clearance; speeds up ammonia reduction, decreases burn in legs - order from http://www.millenniumsports.netor by calling 1800-249-7918. Millennium Sports Carnage - alanine, load for 7 days prior to race to increase intramuscular nitric oxide levels; enhances glucose and muscular oxygen uptake - order from http://www.millenniumsports.netor by calling 1800-249-7918. Millennium Sports Cordgyen5 OR the new Cordygen VO2 - cordyceps, load for 30 days prior to race to improve adrenal activation of lung tissue and enhance VO2max - order from http://www.millenniumsports.netor by calling 1800-249-7918. Millennium Sports Somnidren GH – take 15 minutes prior to bed on an empty stomach (no eating for 2 hours prior) to optimize recovery, deep sleep, and growth hormone release while sleeping - order from http://www.millenniumsports.netor by calling 1800-249-7918. WickedFast RecoverEase - branched chain amino acids, take 4 on training days to enhance recovery, take 8 after a race - order from http://www.recover-ease.com Impax ProstElan - prostate anti-inflammatory for the long time spent in the saddle or for frequentl exercising males - order as "autoship" from 1-800-78-IMPAX:tell them your "enroller number" is 13372 and your "sponsor number" is 12228. Impax EnerPrime - superfood multi-vitamin, too many benefits to list, but primarily for immune system integrity - order as "autoship" from 1-800-78-IMPAX:tell them your "enroller number" is 13372 and your "sponsor number" is 12228. Impax DeltaE - only take as ergogenic aid for caffeine and vitamin B12 megadose content 30-45 minutes prior to race - order as "autoship" from 1-800-78-IMPAX:tell them your "enroller number" is 13372 and your "sponsor number" is 12228. Impax EnerEFA – vegetarian alternative to fish oil, this capsule contains evening primrose oil and flaxseed oil, and should be taken in the morning with breakfast - order as "autoship" from 1-800-78-IMPAX:tell them your "enroller number" is 13372 and your "sponsor number" is 12228. Mt. Capra Probiotics – enhance digestive health, especially useful if you need to take antibiotics and want to maintain healthy balance of good bacteria in the stomach. More information at www.mtcapra.com .

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alberto Espay interview Dr. Ali Rajput about his paper on Parkinson disease subtypes. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about thoracic outlet syndrome and retrograde cerebral embolism. The podcast concludes where Dr. Alberto Espay interviews Dr. Leo Verhagen for our LOTW. The participants had nothing to disclosure except Drs. Rajput, Verhagen and Espay. Dr. Rajput has received honorarium from Novartis, and receives research support from the Parkinson Study Group, Schwartz Biosciences, TEVA, Boehringer-Ingelheim, Saskatchewan Parkinson's Disease Foundation, PrintWest Golf Classic, and Royal University Hospital Foundation. Dr. Verhagen is a consultant for Impax laboratories and Medtronic and speaker for Vernalis and Ipsen. Dr. Espay has received personal compensation as a consultant for Boehringer-Ingelheim, grant support from Codman, Medtronic, Allergan, and CleveMed, and honoraria from UCB-Schwarz Pharma, Medtronic, and Novartis.